{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:53:59Z","timestamp":1777128839273,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":837,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"AstraZeneca LP"},{"name":"AstraZeneca"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck"},{"name":"Abbott"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.jacc.2010.09.082","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T09:01:19Z","timestamp":1302685279000},"page":"1666-1675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":189,"title":["Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol &lt;50 mg\/dl With Rosuvastatin"],"prefix":"10.1016","volume":"57","author":[{"given":"Judith","family":"Hsia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean G.","family":"MacFadyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Monyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2010.09.082_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.082_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.082_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2009.02.040","article-title":"Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID study)","volume":"104","author":"Wiviott","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.09.082_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2008.10.029","article-title":"Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus \u226565 years with coronary heart disease (from the Incremental Decrease Through Aggressive Lipid Lowering [IDEAL] study)","volume":"103","author":"Tikkanen","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.09.082_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","article-title":"Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study)","volume":"100","author":"LaRosa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.09.082_bib6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low?","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.09.082_bib7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.09.082_bib8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMe058052","article-title":"Low-density lipoprotein cholesterol in patients with stable coronary heart disease\u2014is it time to shift our goals?","volume":"352","author":"Pitt","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.082_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200730030-00003","article-title":"Psychiatric adverse reactions with statins, fibrates and ezetimibe","volume":"30","author":"Tatley","year":"2007","journal-title":"Drug Safety"},{"key":"10.1016\/j.jacc.2010.09.082_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00002018-200629010-00002","article-title":"Advances in understanding drug-induced neuropathies","volume":"29","author":"Peltier","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.jacc.2010.09.082_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/jech.2003.013409","article-title":"Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases","volume":"58","author":"Corrao","year":"2004","journal-title":"J Epidemiol Comm Health"},{"key":"10.1016\/j.jacc.2010.09.082_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/07357900600705532","article-title":"Statin use and cancer risk: an epidemiologic review","volume":"24","author":"Friis","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jacc.2010.09.082_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2010.09.082_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ejcn.2009.4","article-title":"Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type diet","volume":"63","author":"Frassetto","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacc.2010.09.082_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4065\/79.1.101","article-title":"Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer","volume":"79","author":"O'Keefe","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2010.09.082_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacc.2010.09.082_bib17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.082_bib18","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.082_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.09.082_bib21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.082_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.082_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.082_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000100908","article-title":"Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program","volume":"107","author":"Shepherd","year":"2007","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2010.09.082_bib25","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/01.ASN.0000136778.32499.05","article-title":"Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells","volume":"15","author":"Verhulst","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2010.09.082_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.38855.610324.80","article-title":"Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study","volume":"333","author":"Ebrahim","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2010.09.082_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/01.STR.20.11.1460","article-title":"Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program","volume":"20","author":"Yano","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.09.082_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0014-4835(90)90012-J","article-title":"On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors","volume":"50","author":"Gerson","year":"1990","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jacc.2010.09.082_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/bjo.79.11.996","article-title":"Absence of effect of simvastatin on the progression of lens opacities in a randomized placebo controlled study","volume":"79","author":"Harris","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jacc.2010.09.082_bib30","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1001\/jama.295.23.2752","article-title":"Statin use and incident nuclear cataract","volume":"295","author":"Klein","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.09.082_bib31","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1001\/archinte.161.16.2021","article-title":"Risk of cataract in patients treated with statins","volume":"161","author":"Schlienger","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2010.09.082_bib32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s002280000248","article-title":"Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?","volume":"56","author":"Gaist","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2010.09.082_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2125.2005.02359.x","article-title":"Statins, lack of energy and ubiquinone","volume":"59","author":"Reidenberg","year":"2005","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.jacc.2010.09.082_bib34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.082_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.082_bib36","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jacc.2008.08.001","article-title":"Low LDL-C levels and cancer","volume":"52","author":"Ben-Yehuda","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.09.082_bib37","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ejca.2008.06.025","article-title":"Statins and cancer: a systematic review and meta-analysis","volume":"44","author":"Kuoppala","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacc.2010.09.082_bib38","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2008.06.037","article-title":"Statins, low-density lipoprotein cholesterol, and risk of cancer","volume":"52","author":"Alsheikh-Ali","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971100444X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971100444X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:44:01Z","timestamp":1760013841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510971100444X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S073510971100444X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.09.082","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10173956.10958055","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg\/dl With Rosuvastatin","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.09.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}